Diagnostic Kit For Screening And Detection Of Gastric Cancer
Pontificia Universidad Católica de Chile
Mauricio Bulnes Bulnes Carrasco
MetadatosMostrar el registro completo del ítem
Our Laboratory Develops And Manufactures Screening Diagnostic Kits For Detection Of Methylated Biomarker Genes Associated With Cancer. Through the International Commercialization And Licensing Of These Products a Future Spinoff Could Sustain a Continuous Research Development And Profitable Revenues. A Key Point is the Market Analysis To Estimate the Potential Demand (locally And Internationally). Our Proposed Technology is a Diagnostic Kit For Screening And Detection Of Gastric Cancer At An Early Stage Based On a Blood Sample. Due To Its Sensibility/specificity Profile And Its Non-invasive Nature It Can Be Used As a Screening Test In High Risk Population. The Target Customer is the Medical Provider (physicians And Medical Insurance Companies) Of Countries With High Risk Of Gastric Cancer Such As Chile Or Most Developed Countries. In These High Risk Zones Where Gastric Cancer is One Of the Leading Cancer-related Deaths a Screening Strategy Based On Our Diagnostic Kit Would Increase Early Stage Diagnosis. Currently the Diagnosis For Gastric Cancer is Performed By An Expensive And Invasive Method the Upper Gastrointestinal Endoscopy Which Requires a Highly Trained Personnel High-end Equipment And Cost Nearly Us$300 1. 000 Depending On the Country. However the Biggest Problem is That the Diagnosis is Often Made In Later Stages Of This Cancer Which Has a Poorer Prognosis. There Isn t a Cost-effective Method For Screening In These High Risk Populations And the Lack Of a Tool For Early Detection Provokes Higher Mortality Rates And a Higher Cost For the Medical System. The Potential Market For This Screening Test is Estimated Up To 3. 7 Million In Chile Alone. Each Year More Than a Million New Cases Are Diagnosed Worldwide And Most Of Them Are In Advanced Stages. There Are Some Countries With Particularly High Incidence Rates And They Have Developed Institutions That Could Help Lower the Barriers Of Entry To Such Markets. Most Eastern Asia And Central And Eastern Europe Have the Highest Incidence Rates And They Are Currently Looking For Efficient Solutions To Help Their Fight As a Whole Against This Kind Of Cancer. Having a Proven Product In Chile Would Be a Strong Appeal To Them. As Such the Biggest Markets For This Technology Reside Outside Chile But If Market Research Proves It This Country Could Be a Good Sample To Estimate the Whole Demand Available Globally.